Showing 1 - 5 results of 5 for search 'Shyamala Navada', query time: 0.02s Refine Results
  1. 1
    PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF

    PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS W... by Andrew Kuykendall, Terrence Bradley, Rami S. Komrokji, Tymara Berry, Souria Dougherty, Laurie Sherman, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, John Mascarenhas

    Published 2023-08-01
    Get full text
    Article
  2. 2
    PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

    PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) by John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian, Katja Sockel, Alessandro Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

    Published 2023-08-01
    Get full text
    Article
  3. 3
    S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

    S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AG... by Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael Sekeres, Michael Robert Savona, Yazan Madanat, María Díez Campelo, David Valcárcel, Thomas Illmer, Anna Jonášová, Petra Belohlavkova, Laurie Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Lixian Peng, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shyamala Navada, Rami S. Komrokji, Amer M. Zeidan

    Published 2023-08-01
    Get full text
    Article
  4. 4
    S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

    S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATIN... by Valeria Santini, Uwe Platzbecker, Pierre Fenaux, Mikkael Sekeres, Michael Robert Savona, Yazan Madanat, María Díez Campelo, David Valcárcel, Thomas Illmer, Anna Jonášová, Petra Belohlavkova, Laurie Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Lixian Peng, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shyamala Navada, Faye Feller, Amer M. Zeidan, Rami S. Komrokji

    Published 2023-08-01
    Get full text
    Article
  5. 5
    P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

    P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS... by Mikkael Sekeres, Valeria Santini, María Díez Campelo, Rami S. Komrokji, Pierre Fenaux, Michael Robert Savona, Yazan Madanat, David Valcárcel, Thomas Illmer, Anna Jonášová, Petra Belohlavkova, Antoine Regnault, Kristin Creel, Nishan Sengupta, Laurie Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shyamala Navada, Faye Feller, Amer M. Zeidan, Uwe Platzbecker

    Published 2023-08-01
    Get full text
    Article

Search Tools: